Full text is available at the source.
Abstract
Facial volume depletion and skin laxity are increasingly reported during weight loss associated with glucagon-like peptide-1 receptor agonist treatment.
- These changes may not be recognized as a distinct clinical entity.
- Facial volume depletion and skin laxity could overlap with effects from other forms of rapid or massive weight loss.
- Evidence regarding effective treatments for these changes remains limited.
Simplified